Aligos Therapeutics (NASDAQ:ALGS) Downgraded by Wall Street Zen to “Sell”

Aligos Therapeutics (NASDAQ:ALGS) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other research firms have also issued reports on ALGS. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Wednesday, January 21st. UBS Group began coverage on shares of Aligos Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $20.00 price objective for the company. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $35.00.

Aligos Therapeutics Price Performance

Shares of NASDAQ ALGS opened at $6.98 on Friday. The business has a fifty day moving average price of $7.88 and a two-hundred day moving average price of $9.07. The stock has a market capitalization of $42.93 million, a PE ratio of -0.81 and a beta of 2.67. Aligos Therapeutics has a fifty-two week low of $3.76 and a fifty-two week high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Monday, March 9th. The company reported ($1.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.09) by $0.18. Aligos Therapeutics had a negative return on equity of 25.01% and a negative net margin of 1,106.72%.The company had revenue of $0.17 million for the quarter. On average, equities analysts expect that Aligos Therapeutics will post -10.36 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Sio Capital Management LLC increased its stake in Aligos Therapeutics by 85.9% during the 2nd quarter. Sio Capital Management LLC now owns 335,937 shares of the company’s stock valued at $2,422,000 after purchasing an additional 155,217 shares in the last quarter. Verition Fund Management LLC acquired a new position in Aligos Therapeutics during the 4th quarter valued at about $664,000. LPL Financial LLC increased its holdings in Aligos Therapeutics by 19.7% during the 4th quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock worth $615,000 after purchasing an additional 10,880 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in Aligos Therapeutics by 64.0% during the 3rd quarter. Squarepoint Ops LLC now owns 30,493 shares of the company’s stock worth $299,000 after acquiring an additional 11,904 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Aligos Therapeutics by 21.3% during the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after buying an additional 5,978 shares in the last quarter. 60.43% of the stock is owned by institutional investors and hedge funds.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.